Mayank Mantami
Analyst, B. Riley Securities
Replay available
PDS Biotechnology Corporation (PDSB) Q2 2025 Earnings Call
PDS Biotechnology Corporation (NASDAQ: PDSB) Q2 2025 earnings conference call, held 2025-08-13. Replay captured from the company's public earnings webcast.
Hosted by
Featured presenters
Dr. Frank Badu-Addo
Chief Executive Officer
Dr. Kirk Shepard
Chief Medical Officer
Lars Bosgaard
Chief Financial Officer
Mike Moyer
Investor Relations, Lakeside Advisors
Investor webinar replay
Watch the replay and follow the connected company analysis, news, and investor updates for Pds Biotechnology Corporation.
Replay transcript excerpt
WEBVTT 00:00:01.617 -- 00:00:06.762 Greetings. Welcome to PDS Biotech Second Quarter 2025 Earnings Conference 00:00:06.762 -- 00:00:10.746 Call. At this time, all participants are in a listen-only mode. 00:00:10.746 -- 00:00:14.570 A question and answer session will follow the formal presentation. 00:00:14.570 -- 00:00:18.854 If anyone should require operator assistance, please press star zero on your telephone 00:00:18.854 -- 00:00:22.858 keypad. As a reminder, this conference is being recorded. 00:00:22.858 -- 00:00:26.462 It is now my pleasure to introduce Mike Moyer with Lakeside Advisors. 00:00:26.462 -- 00:00:29.143 Thank you. You may begin. 00:00:29.663 -- 00:00:33.870 Thank you, operator. Good morning, everyone, and welcome to PDS Biotech's second quarter 00:00:33.870 -- 00:00:38.277 2025 results and clinical programs update call. 00:00:38.277 -- 00:00:41.943 I'm joined on the call today by the following members of the company's management team. 00:00:41.943 -- 00:00:45.368 Dr. Frank Badu-Addo, Chief Executive Officer, Dr. 00:00:45.368 -- 00:00:49.355 Kirk Shepard, Chief Medical Officer, and Lars Bosgaard, 00:00:49.355 -- 00:00:53.822 Chief Financial Officer. Dr. Badu-Addo will begin with an overview of the company's recent 00:00:53.822 -- 00:00:56.612 progress in its clinical development program, Mr. 00:00:56.612 -- 00:01:01.960 Boesgaard will then review the financial results for the quarter ended June 30, 2025, 00:01:01.960 -- 00:01:05.906 and Dr. Shepherd will join the call to help address questions from covering analysts 00:01:05.906 -- 00:01:10.672 during the Q&A. As a reminder, during this call, we will be making forward-looking statements 00:01:10.672 -- 00:01:14.838 which are subject to various risks and uncertainties that could cause our actual resu...